Abstract:RNA editing, an essential post -transcriptional reaction occurring in double -stranded RNA (dsRNA), generates informational diversity in the transcriptome and proteome. In mammals, the main type of RNA editing is the conversion of adenosine to inosine (A -to -I), processed by adenosine deaminases acting on the RNAs (ADARs) family, and interpreted as guanosine during nucleotide base -pairing. It has been reported that millions of nucleotide sites in human transcriptome undergo A -to -I editing events, catalyzed by the primarily responsible enzyme, ADAR1. In hematological malignancies including myeloid/lymphocytic leukemia and multiple myeloma, dysregulation of ADAR1 directly impacts the A -to -I editing states occurring in coding regions, noncoding regions, and immature miRNA precursors. Subsequently, aberrant A -to -I editing states result in altered molecular events, such as protein -coding sequence changes, intron retention, alternative splicing, and miRNA biogenesis inhibition. As a vital factor of the generation and stemness maintenance in leukemia stem cells (LSCs), disordered RNA editing drives the chaos of molecular regulatory network and ultimately promotes the cell proliferation, apoptosis inhibition and drug resistance. At present, novel drugs designed to target RNA editing (e.g., rebecsinib) are under development and have achieved outstanding results in animal experiments. Compared with traditional antitumor drugs, epigenetic antitumor drugs are expected to overcome the shackle of drug resistance and recurrence in hematological malignancies, and provide new treatment options for patients. This review summarized the recent advances in the regulation mechanism of ADAR1-mediated RNA editing events in hematologic malignancies, and further discussed the medical potential and clinical application of ADAR1.

The role of dsRNA A-to-I editing catalyzed by ADAR family enzymes in the pathogeneses

The role of RNA editing enzyme ADAR1 in human disease

The role of ADAR1 through and beyond its editing activity in cancer

Adenosine Deaminase Acting on RNA 1 (ADAR1) As Crucial Regulators in Cardiovascular Diseases: Structures, Pathogenesis, and Potential Therapeutic Approach

RNA Editing, ADAR1, and the Innate Immune Response

Mechanisms and Implications of ADAR-mediated RNA Editing in Cancer

Biological roles of A-to-I editing: implications in innate immunity, cell death, and cancer immunotherapy.

Harnessing ADAR-Mediated Site-Specific RNA Editing in Immune-Related Disease: Prediction and Therapeutic Implications

ADAR-mediated RNA Editing in Non-Coding RNA Sequences

Origins And Evolution Of Adar-Mediated Rna Editing

An RNA editing/dsRNA binding-independent gene regulatory mechanism of ADARs and its clinical implication in cancer

Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity

Origins and Evolution of ADAR‐mediated RNA Editing

ADAR1-Mediated RNA Editing and Its Role in Cancer

The RNA-editing enzyme ADAR1: a regulatory hub that tunes multiple dsRNA-sensing pathways

A-to-I editing of coding and non-coding RNAs by ADARs

Site-directed RNA editing by harnessing ADARs: advances and challenges

Adenosine Deaminases Acting on RNA, RNA Editing, and Interferon Action

New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins

Adenosine-to-Inosine RNA Editing: A Key RNA Processing Step Rewriting Transcriptome in Normal Physiology and Diseases

The Regulatory Function of ADAR1-mediated RNA Editing in Hematological Malignancies